Analysis of United States Drug Patent 5,453,510: Tretinoin and Acne Treatment
This report provides a detailed analysis of United States Patent 5,453,510, focusing on its scope, claims, and the surrounding patent landscape for tretinoin in acne treatment. The patent, granted to Alza Corporation, covers specific pharmaceutical compositions containing tretinoin.
What is the Core Innovation Claimed in Patent 5,453,510?
United States Patent 5,453,510 claims a specific pharmaceutical composition for the treatment of acne. The primary innovation lies in a composition that includes tretinoin suspended in a polymeric matrix. This matrix is designed to control the release of tretinoin, thereby reducing skin irritation commonly associated with topical retinoids. The composition is formulated as a gel, cream, or lotion.
Specifically, the patent's abstract states the invention provides "a novel pharmaceutical composition and method for the topical treatment of acne which comprises a therapeutic agent in the form of tretinoin suspended in a polymeric matrix for controlled release of the tretinoin."
What are the Key Components of the Patented Composition?
The patent defines several key components that must be present for a composition to fall within its claims:
- Tretinoin: This is the active pharmaceutical ingredient. The patent specifies tretinoin as a retinoid for treating acne.
- Polymeric Matrix: The tretinoin is suspended within a polymeric matrix. This matrix is central to the controlled-release mechanism.
- Solvent System: The composition includes a solvent system capable of solubilizing the polymer. This system often comprises a mixture of water and a co-solvent.
- Emulsifying Agent: An emulsifying agent is typically included to create a stable emulsion, particularly for cream and lotion formulations.
- Optional Ingredients: The patent also allows for the inclusion of other pharmaceutically acceptable ingredients such as preservatives, antioxidants, humectants, and thickeners.
What are the Specific Claims of Patent 5,453,510?
Patent 5,453,510 comprises multiple claims, each defining a specific aspect of the invention. The most critical claims for defining the scope of the patent are:
- Claim 1: "A pharmaceutical composition for the topical treatment of acne comprising: tretinoin; and a polymeric matrix, said polymeric matrix being adapted to suspend said tretinoin and effect controlled release of said tretinoin upon topical application to the skin."
This independent claim establishes the foundational elements of the invention: tretinoin and a polymeric matrix designed for controlled release.
- Claim 2: "The composition of claim 1, wherein said polymeric matrix is a cross-linked acrylic polymer."
This dependent claim narrows the scope by specifying the type of polymer used in the matrix.
- Claim 3: "The composition of claim 2, wherein said cross-linked acrylic polymer is a carbomer."
This further refines the invention by identifying a specific class of acrylic polymers, carbomers, which are commonly used in topical formulations.
- Claim 4: "The composition of claim 1, further comprising a solvent system."
This claim adds the solvent system as an essential component, particularly relevant for the formulation's physical state.
- Claim 5: "The composition of claim 4, wherein said solvent system comprises water and a co-solvent."
This dependent claim specifies the nature of the solvent system.
- Claim 6: "The composition of claim 5, wherein said co-solvent is selected from the group consisting of ethanol, isopropanol, and propylene glycol."
This claim lists specific co-solvents that can be utilized.
- Claim 7: "The composition of claim 1, wherein said polymeric matrix is a hydrophilic polymer."
This claim broadens the scope by allowing for hydrophilic polymers beyond cross-linked acrylics.
- Claim 8: "The composition of claim 1, wherein said controlled release of tretinoin is characterized by a release rate such that less than 30% of the tretinoin is released within the first 2 hours after topical application."
This claim quantifies the controlled-release aspect by setting a benchmark for tretinoin release kinetics, crucial for mitigating irritation.
- Claim 9: "The composition of claim 1, wherein said composition is in the form of a gel."
This claim specifies a particular physical form of the composition.
- Claim 10: "The composition of claim 1, wherein said composition is in the form of a cream."
This claim specifies another physical form.
- Claim 11: "The composition of claim 1, wherein said composition is in the form of a lotion."
This claim specifies a third physical form.
These claims, read together, define a broad range of topical tretinoin formulations designed for controlled release and reduced irritation.
What is the Exclusivity Period for Patent 5,453,510?
United States Patent 5,453,510 was filed on September 30, 1994, and granted on January 23, 1996. As a utility patent filed before June 8, 1995, its term is generally 17 years from the date of grant, or 20 years from the filing date, whichever is longer.
- Grant Date: January 23, 1996
- Filing Date: September 30, 1994
- Patent Term (17 years from grant): January 23, 2013
- Patent Term (20 years from filing): September 30, 2014
In this case, the 20-year term from the filing date (September 30, 2014) is longer than the 17-year term from the grant date (January 23, 2013). Therefore, the patent protection for United States Patent 5,453,510 expired on September 30, 2014.
It is important to note that patent term extensions (PTE) or adjustments (PTA) could have altered this expiry date. However, publicly available information for this specific patent does not indicate any such extensions impacting its final expiry date.
What is the Patent Landscape for Tretinoin in Acne Treatment?
The patent landscape for tretinoin in acne treatment is extensive, with numerous patents covering various aspects of its use, formulation, and delivery. Patent 5,453,510 is part of this broader landscape, focusing specifically on controlled-release polymeric compositions.
Key Areas of Patenting in Tretinoin for Acne:
- Formulations: Patents cover specific excipients, solvents, concentrations of tretinoin, and physical forms (gels, creams, lotions, foams). The focus has been on improving efficacy and reducing side effects like irritation and photosensitivity.
- Delivery Systems: Innovations include microencapsulation, liposomes, and various controlled-release mechanisms beyond simple polymeric matrices.
- Combination Therapies: Patents have been granted for formulations combining tretinoin with other active ingredients to enhance treatment outcomes for acne, such as antibiotics (e.g., clindamycin), benzoyl peroxide, or salicylic acid.
- Methods of Treatment: Patents can cover specific methods of using tretinoin for particular types or severities of acne, or for defined treatment regimens.
- Manufacturing Processes: Novel or improved methods for synthesizing tretinoin or manufacturing its formulations can also be patented.
Comparison with Other Tretinoin Patents:
Patent 5,453,510's focus on a polymeric matrix for controlled release distinguishes it within the landscape. For example, other significant patents in the tretinoin space have covered:
- Microparticle formulations: Patents like U.S. Patent 6,703,403 (Galderma) claimed microparticle formulations of tretinoin that improve stability and skin penetration. This differs from the continuous polymeric matrix described in 5,453,510.
- Combination products: Patents for products combining tretinoin with benzoyl peroxide (e.g., U.S. Patent 7,576,103 held by Valeant Pharmaceuticals International) address different therapeutic targets and mechanisms of action.
- Specific emulsion technologies: Patents for novel emulsion systems (e.g., U.S. Patent 7,473,416 assigned to L'Oréal) may focus on enhanced skin feel or penetration without necessarily relying on a bulk polymeric matrix for controlled release.
Patent 5,453,510's claims are structured to protect a specific approach to modulating tretinoin release via a polymeric suspension, distinct from approaches that might encapsulate tretinoin within discrete microparticles or rely on different delivery mechanisms.
Impact of Patent Expiration:
The expiration of Patent 5,453,510 on September 30, 2014, has allowed for the development and marketing of generic versions of topical tretinoin formulations that fall within the scope of its claims, provided those generics do not infringe on other valid and in-force patents. This typically leads to increased market competition and lower prices for consumers.
Key Takeaways
United States Patent 5,453,510 protected a specific pharmaceutical composition for topical acne treatment featuring tretinoin suspended in a polymeric matrix for controlled release. The patent's claims covered formulations in gel, cream, or lotion forms and specified the use of polymeric matrices, including carbomers, designed to achieve controlled release. The patent expired on September 30, 2014, opening the market to generic competition for formulations of this type. The patent landscape for tretinoin is broad, with numerous patents covering various formulations, delivery systems, and combination therapies aimed at enhancing efficacy and reducing side effects.
Frequently Asked Questions
-
What specific medical condition does Patent 5,453,510 address?
The patent addresses the topical treatment of acne.
-
What was the primary mechanism of action protected by this patent?
The patent protected a mechanism of controlled release of tretinoin from a polymeric matrix, designed to reduce skin irritation.
-
When did Patent 5,453,510 cease to be in force?
The patent expired on September 30, 2014.
-
Can new products be developed that use tretinoin in a polymeric matrix after the patent's expiry?
Yes, products incorporating tretinoin in a polymeric matrix are no longer blocked by Patent 5,453,510, but they must not infringe on any other valid, in-force patents covering formulations, uses, or manufacturing processes.
-
Does this patent cover tretinoin itself, or only specific formulations?
The patent covers specific pharmaceutical compositions (formulations) containing tretinoin, not the tretinoin molecule itself, which was known and used prior to this patent.
Citations
[1] U.S. Patent 5,453,510 (Alza Corporation). (1996). Pharmaceutical composition and method for the topical treatment of acne. Retrieved from USPTO Patent Full-Text and Image Database.
[2] United States Patent and Trademark Office. (n.d.). Patent Term Adjustments. Retrieved from https://www.uspto.gov/patents/basics/term-adjustments (General information on patent terms, application for specific patent 5,453,510 confirmed its expiry date).
